Table 1.

IL-1β, sIL-1RII, and IL-1Ra in the culture supernatants of PMN and PBMC from control and patients with Lyme disease.

	Control n = 30		Patients n = 43
	PMN	PBMC	PMN	PBMC
	$\overline{x}$ ± SD	$\overline{x}$ ± SD	$\overline{x}$ ± SD	$\overline{x}$ ± SD
IL-1β (pg/mL)
Unstimulated cells	7 ± 3.7	13 ± 7 b	8.8 ± 2.8	18 ± 3.9 b
LPS-stimulated	22 ± 7.6 a	46 ± 13 a b	13 ± 4.9 a *	39 ± 12 a b
rhIL-15 stimulated	28 ± 10 a	40 ± 14 a b	11 ± 3 a *	32 ± 10 a b
sIL-1RII (ng/mL)
Unstimulated cells	0.6 ± 0.2	0.6 ± 0.2	0.9 ± 0.5*	1 ± 0.4 b *
LPS-stimulated	1 ± 0.2 a	1 ± 0.3 a	1 ± 0.5	1.7 ± 0.4 b *
rhIL-15 stimulated	0.9 ± 0.3 a	0.9 ± 0.2 a	1 ± 0.5	1.6 ± 0.5 b *
IL-1Ra (ng/mL)
Unstimulated cells	0.6 ± 0.2	0.5 ± 0.2	0.6 ± 0.3	0.4 ± 0.2
LPS-stimulated	1 ± 0.4 a	1 ± 0.4 a	0.8 ± 0.3 a	1 ± 0.7 a
rhIL-15 stimulated	1 ± 0.3 a	1 ± 0.3 a	1.4 ± 0.4 a	1.8 ± 0.9 a

*Statistical differences between control and patients groups (P < .001).

^aStatistical differences between unstimulated cells and cells incubated with LPS or rhIL-15 (P < .001).

^bStatistical differences between PMN and PBMC (P < .001).